From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study
Aspirin user | Aspirin non-user | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Mortality | Patients | Person years | Mortality | Patients | Person years | Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
CRC-specific survival | ||||||||||
Post-diagnostic aspirin use (fixed time exposure in first year)a | ||||||||||
Aspirin user vs. non-user | 310 | 2150 | 5692 | 754 | 6241 | 16,442 | 1.19 (1.05, 1.36) | 0.01 | 1.10 (0.94, 1.29) | 0.22 |
Post-diagnostic aspirin use versus non-use stratified by pre-diagnostic use (excludes 2009 cases)b | ||||||||||
Pre-diagnostic users | 168 | 1333 | 2983 | 46 | 257 | 614 | 0.75 (0.54,1.04) | 0.08 | 0.80 (0.56,1.13) | 0.20 |
Pre-diagnostic non-users | 51 | 435 | 744 | 467 | 4301 | 9930 | 1.52 (1.13,2.03) | 0.01 | 1.51 (1.12,2.05) | 0.01 |
Aspirin use vs. non-use in year before colorectal cancer diagnosis (excludes 2009 cases)c | ||||||||||
Aspirin user vs. non-user | 1104 | 2853 | 6460 | 2551 | 7555 | 18,652 | 1.23 (1.14, 1.32) | < 0.001 | 0.96 (0.88, 1.05) | 0.37 |